Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years – CNBC

Business News

  1. Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years  CNBC
  2. Semaglutide, or Ozempic, reduces symptoms of feared diabetes’ complication, study finds  The Globe and Mail
  3. STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients  TCTMD
  4. SOUL: Oral Semaglutide Cuts MACE by 14% in People with Type 2 Diabetes  MD Magazine
  5. Rybelsus Reduces Cardiovascular Risk by 14% in New Trial | ACC 2025  Managed Healthcare Executive

Source: Business News

/by